Journal
HUMAN MOLECULAR GENETICS
Volume 21, Issue 3, Pages 681-691Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddr501
Keywords
-
Funding
- NIH [MH080434, MH078972]
- Waisman Center from the NIH [P30 HD03352]
Ask authors/readers for more resources
Fragile X syndrome (FXS), a common inherited form of intellectual disability with learning deficits, results from a loss of fragile X mental retardation protein (FMRP). Despite extensive research, treatment options for FXS remain limited. Since FMRP is known to play an important role in adult hippocampal neurogenesis and hippocampus-dependent learning and FMRP regulates the adult neural stem cell fate through the translational regulation of glycogen synthase kinase 3b (GSK3b), we investigated the effects of a GSK3b inhibitor, SB216763, on Fmr1 knockout mice (Fmr1 KO). We found that the inhibition of GSK3b could reverse the hippocampus-dependent learning deficits and rescue adult hippocampal neurogenesis at multiple stages in Fmr1 KO mice. Our results point to GSK3b inhibition as a potential treatment for the learning deficits seen in FXS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available